Deep Dive · News · ThePouchVault
ZYN’s FDA Modified Risk Authorization:
The Full Story
The Authorized Claim — Word for Word
The MRTP order authorizes Swedish Match USA — the Philip Morris International subsidiary that manufactures ZYN — to market 20 specific products with the following claim:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
The precision of this language matters. It says “lower risk” — not “no risk.” It says “instead of cigarettes” — not “instead of all tobacco products.” It names six specific diseases: mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. Every word in that claim was scrutinized by the FDA during a years-long review process before being authorized. This is not marketing copy. It’s a regulatory finding.
What Is a Modified Risk Tobacco Product?
The Modified Risk Tobacco Product designation is a specific regulatory category created under the Family Smoking Prevention and Tobacco Control Act, which gave the FDA authority over tobacco products. MRTP status allows a manufacturer to market a product with claims that it presents reduced risk or reduced exposure compared to other tobacco products — but only after the FDA has completed an extensive scientific review and concluded those claims are accurate.
There are two types of MRTP authorization. A “risk modification” order — which is what ZYN received — requires the manufacturer to demonstrate that the product actually reduces the risk of tobacco-related disease. A “exposure modification” order is a lower bar, only requiring proof of reduced exposure to harmful chemicals without necessarily proving disease risk reduction. ZYN cleared the higher bar.
The key distinction: MRTP is not the same as FDA “approval” in the pharmaceutical drug sense. The FDA isn’t saying ZYN is safe or recommending its use. It is saying that the specific reduced-risk claim Swedish Match applied for is scientifically accurate, that consumers understand it correctly, and that allowing it to be marketed with that claim would benefit the population as a whole — primarily by giving adult smokers accurate information to make informed switching decisions.
The Timeline: How We Got Here
The Science the FDA Based This On
The MRTP application did not include long-term clinical trials directly measuring health outcomes in ZYN users — that would take decades of follow-up data that doesn’t yet exist for a relatively new product category. Instead, the FDA’s decision drew on several bodies of existing evidence:
The FDA largely based its risk reduction conclusion on decades of epidemiological data from Swedish snus — a smokeless tobacco product with similar use characteristics to nicotine pouches. Swedish snus research spanning 40+ years consistently shows dramatically lower rates of smoking-related cancers among snus users compared to smokers.
ZYN pouches contain substantially lower amounts of harmful and potentially harmful constituents (HPHCs) than cigarettes and most smokeless tobacco products. No combustion means no smoke toxicants. No tobacco leaf means no tobacco-specific nitrosamines at the levels found in traditional tobacco products.
The FDA evaluated whether adult consumers understand the authorized claim correctly — specifically, whether people would interpret “lower risk than cigarettes” as meaning “safe” or “no risk.” The studies showed consumers generally understood the relative nature of the claim without misinterpreting it as absolute safety.
A major component of the FDA’s review was evaluating whether marketing ZYN with a modified risk claim would increase youth uptake. The FDA concluded that allowing the claim would benefit the population as a whole — meaning the benefit to adult smokers who might switch outweighs the risk of increased youth initiation.
Swedish Match provided evidence from studies showing that a substantial proportion of adults who use cigarette and/or smokeless tobacco products completely switched to ZYN. Complete switching — not dual use — is the key metric for population health benefit.
The FDA assessed whether marketing ZYN with reduced-risk claims would benefit the population as a whole, considering both the potential reduction in smoking-related disease among adult switchers and the potential for increased nicotine initiation among non-users. The net assessment was positive.
What the MRTP Authorization Does and Doesn’t Mean
- Swedish Match can legally advertise ZYN’s lower risk vs. cigarettes in the US
- The specific six-disease risk reduction claim is scientifically validated
- Adult smokers have FDA-authorized information to make informed switching decisions
- ZYN is the first nicotine pouch to reach this regulatory milestone globally
- The science supports meaningful risk reduction for complete cigarette switchers
- Consumer understanding of the relative claim is validated
- ZYN is not “safe” — no tobacco product is approved as safe by the FDA
- This is not a recommendation to use ZYN if you don’t currently use nicotine
- The authorization doesn’t apply in Canada — Health Canada has not issued equivalent authorization
- Risk reduction applies to complete switching — not dual use with cigarettes
- Long-term health outcomes in ZYN users specifically haven’t been measured
- Canadian retailers cannot make modified risk marketing claims
PMI’s Response — What They Said
Philip Morris International CEO for the US, Stacey Kennedy, called the decision an important moment for nicotine consumers: the authorization ensures adult smokers have access to accurate, science-based information about the lower risks associated with switching from cigarettes to ZYN.
PMI noted that its smoke-free products are available in over 105 markets globally and were used by over 43 million legal-age consumers as of the end of 2025. Smoke-free products now account for 43% of PMI’s first-quarter 2026 total net revenues — a figure that underscores how significant the category has become for the company and how seriously the industry is treating harm reduction as a commercial and regulatory priority.
What This Means for Canadian ZYN Users
The FDA’s decision is a US regulatory ruling — and its direct legal effects stop at the border. Health Canada has not issued equivalent Modified Risk authorization, and Canadian retailers cannot make the modified risk claim in their marketing. That’s an important and non-negotiable distinction.
What doesn’t stop at the border is the science. The same ZYN products authorized by the FDA are available in Canada. The same chemical composition data, the same reduced harmful constituent profile, the same basis for the FDA’s conclusion — all of that applies to the cans on Canadian shelves identically to those on US shelves. The regulatory label is different. The product is the same.
For Canadian smokers considering the switch: The FDA’s ruling is the most significant independent scientific validation the nicotine pouch category has ever received. It doesn’t change Canadian regulations, but it does provide authoritative, peer-reviewed, government-level confirmation of what the science on ZYN’s risk profile actually says. That’s meaningful context for any adult smoker weighing their options — regardless of which side of the border they’re on.
Frequently Asked Questions
The FDA did not “approve” ZYN in the pharmaceutical sense. It issued Modified Risk Tobacco Product orders that authorize Swedish Match to market 20 ZYN products with a specific claim that using them instead of cigarettes reduces the risk of six specific diseases. The products were already authorized for sale in the US since January 2025 — this ruling specifically authorizes the risk reduction marketing claim.
Because nicotine pouches are a relatively new product category and long-term health outcome data specific to ZYN users doesn’t yet exist — it takes decades of follow-up to measure cancer outcomes in a population. Swedish snus has been widely used in Scandinavia for over a century and has an extensive epidemiological record. The FDA accepted the snus data as a valid proxy given the similar use characteristics, nicotine content, and systemic exposure profile of ZYN products.
No — this is a US FDA ruling. Health Canada has not issued equivalent authorization, and Canadian retailers cannot make modified risk marketing claims. ZYN remains legal to purchase and use in Canada for adults 19+ regardless of this ruling. The science behind it applies globally, but the regulatory authorization is US-specific.
Swedish Match can apply to renew the orders before they expire. The FDA will review ongoing postmarket surveillance data — including any new evidence on youth uptake rates, consumer understanding of the claim, and population health impact — before deciding whether to renew the authorization as-is, modify it, or withdraw it.
The FDA’s ruling is not a medical recommendation. It’s an authorization for a specific marketing claim about relative risk. If you’re a smoker trying to quit, the most important step is to speak with your healthcare provider about your options. The ruling does confirm that the science supports meaningful risk reduction for those who switch completely from cigarettes to ZYN — but what’s right for any individual is a personal health decision.
Explore Nicotine Pouches at ThePouchVault
Interested in making the switch from cigarettes? Browse our full selection — White Fox, Zolt, Pablo, Clew and more — shipped next-day from Fergus, Ontario. Canada Post tracked delivery coast to coast.
Use code WELCOME10 for 10% off your first order.
⚠️ This article is for informational purposes only. The FDA’s Modified Risk Tobacco Product authorization applies in the United States only. Health Canada has not issued equivalent authorization. ThePouchVault does not make health claims about any product sold on this site. Nicotine pouches contain nicotine, which is addictive. For adult nicotine consumers 19+ only. Not intended for non-nicotine users, persons under 19, pregnant or breastfeeding women, or those with heart conditions. If you are considering switching from cigarettes, consult your healthcare provider.